Advances in comprehensive treatment of initially unresectable liver metastasis from colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2021.04.013

Abstract

Abstract:

The metastasis rate of liver metastases of colorectal carcinoma is very high. Only about 20%~30% of patients with colorectal cancer with liver metastasis are initially resectable. The potentially unresectable and unresectable colorectal cancer with liver metastases make up the majority of patients. It is a key issue for clinicians to make the patients benefit from chemotherapy, targeted therapy, immunotherapy, surgical treatment and other comprehensive treatments. In recent years, some progress has been made in the comprehensive treatment of colorectal cancer patients with liver metastasis.

Key words: Colorectal neoplasms, Colorectal liver metastases, Comprehensive treatment

Peipei Wang, Bin Wu. Advances in comprehensive treatment of initially unresectable liver metastasis from colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(04): 409-412.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2021.04.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2021/V10/I04/409

References 29

1	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA: A Cancer Journal for Clinicians, 2020, 70(1): 7-30.
2	Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J]. Chinese Journal of Cancer Research, 2018, 30(1): 1-12.
3	Xu J, Fan J, Qin X, et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018) [J]. Journal of Cancer Research and Clinical Oncology, 2019, 145(3): 725-736.
4	Shin SW, Ahn KS, Kim SW, et al. Liver resection versus local ablation therapies for hepatocellular carcinoma within the milan criteria: a systematic review and meta-analysis[J]. Annals of Surgery, 2021, 273(4): 656-666.
5	Orcutt ST, Anaya DA. Liver resection and surgical strategies for management of primary liver cancer[J]. Cancer Control: Journal of the Moffitt Cancer Center, 2018, 25(1): 1073274817744621.
6	Scherman P, Syk I, Holmberg E, et al. Impact of patient, primary tumor and metastatic pattern including tumor location on survival in patients undergoing ablation or resection for colorectal liver metastases: A population-based national cohort study[J]. European Journal of Surgical Oncology: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, 47(2): 375-383.
7	Rouyer M, François E, Cunha AS, et al. Effectiveness of cetuximab as first-line therapy for patients with wild-type KRAS and unresectable metastatic colorectal cancer in real-life practice: results of the EREBUS cohort[J]. Clinical colorectal cancer, 2018, 17(2): 129-139.
8	Chen HH, Lin JK, Chen JB, et al. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase Ⅱ, open-label, single-arm, noncomparative trial[J]. Asia-Pacific Journal of Clinical Oncology, 2018, 14(1): 61-68.
9	Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) [J]. European Journal of Cancer (Oxford, England: 1990), 2017, 81: 191-202.
10	Takahashi T, Emi Y, Oki E, et al. Multicenter phase Ⅱ study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) [J]. Cancer Chemotherapy and Pharmacology, 2016, 78(3): 585-593.
11	Lévi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2016, 27(2): 267-274.
12	Grothey A, Blay JY, Pavlakis N, et al. Evolving role of regorafenib for the treatment of advanced cancers[J]. Cancer Treatment Reviews, 2020, 86: 101993.
13	Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer[J]. European Journal of Cancer (Oxford, England: 1990), 2019, 109: 70-83.
14	Walter T, Hawkins NS, Pollock RF, et al. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer[J]. Journal of Cancer Research and Clinical Oncology, 2020, 146(10): 2575-2587.
15	Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: Past, present, and future[J]. Genes & Diseases, 2020, 7(3): 328-335.
16	Kim JH, Kim SY, Kim KP, et al. Regorafenib-induced hypothyroidism as a predictive marker for improved survival in metastatic or unresectable colorectal cancer refractory to standard therapies: a prospective single-center study[J]. Targeted Oncology, 2019, 14(6): 689-697.
17	Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nature Medicine, 2020, 26(4): 566-576.
18	News in Brief. PD-1 inhibitor bests chemo for colorectal cancer[J]. Cancer discovery, 2020, 10(7): Of2.
19	André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. The New England Journal of Medicine, 2020, 383(23): 2207-2218.
20	Fumet JD, Isambert N, Hervieu A, et al. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer[J]. ESMO Open, 2018, 3(4): e000375.
21	Park EJ, Baek JH, Choi GS, et al. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: a multicenter randomized controlled trial[J]. Cancers, 2020, 12(8): 2306.
22	Ergun Y, Bal O, Dogan M, et al. Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?[J] Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences, 2020, 25: 14.
23	Fiorentini G, Sarti D, Aliberti C, et al. Chemoembolization in conjunction with bevacizumab: Preliminary results[J]. Journal of Vascular and Interventional Radiology: JVIR, 2018, 29(9): 1236-1239.
24	Wei N, Zhang B, Wang Y, et al. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis[J]. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, 21(4): 443-450.
25	Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase Ⅱ trial[J]. Journal of the National Cancer Institute, 2017, 109(9): djx015.
26	Larsen FO, Jensen BV, Nørgaard HH, et al. Intrahepatic oxaliplatin and systemic 5-FU +/- cetuximab in chemo-naïve patients with liver metastases from colorectal cancer[J]. Oncology, 2019, 96(6): 299-308.
27	Coletti L, Battaglia V, De Simone P, et al. Safety and feasibility of electrochemotherapy in patients with unresectable colorectal liver metastases: A pilot study[J]. International Journal of Surgery (London, England), 2017, 44: 26-32.
28	Scorsetti M, Comito T, Clerici E, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up[J]. Radiation Oncology (London, England), 2018, 13(1): 234.
29	Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial[J]. The British Journal of Surgery, 2019, 106(13): 1837-1846.

[1]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[2]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[3]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[4]	Shengjun Zhang, Ajing Zhao, Shoubo Li, Xianghong Hao, Minli Liu. An experimental study on the promotion of colorectal cancer invasion and migration by high glucose through HGF/c-met pathway [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 21-24.
[5]	Ting Li, Lin Zhang. Relationship between serum fatty acid metabolites and vitamin D levels and colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 661-665.
[6]	Wenkai Ni, Chong Qi, Xiaodan Xu, Xiecheng Zhou, Qingzhang Yin, Yuankun Cai. Analysis of influencing factors of prolonged postoperative ileus in patients with colorectal cancer after operation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 484-489.
[7]	Xiaoyu Fan, Sizheng Sun, Yimin E, Chunzhao Yu. Different surgical options for obstructive left colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 500-504.
[8]	Xu Guan, Xishan Wang. Reflecting on the merits and demerits of regional lymph node management in colorectal cancer based on surgical and immune perspectives [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 448-452.
[9]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[10]	Wenyun Hou, Hengchang Liu, Lizhou Dou, Haipeng Chen, Zhaoxu Zheng, Guiqi Wang, Xishan Wang. A case of total laparoscopic radical surgery for right colon cancer with colonoscope-assisted transluminal extraction of specimen without auxiliary incision (ileocecal junction preservation) [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 436-440.
[11]	Yicheng Huang, Chen Lu, Sizheng Sun, Chunzhao Yu. Expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 396-403.
[12]	Qi Liu, Kai Zhang, Jiannan Li, Tongjun Liu. Current status and progress of biologic treatment for colorectal cancer liver metastases [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 415-419.
[13]	Yin Wu, Zhiqin Chen, Yong Gao, Ming Quan. Progress in diagnosis and treatment of Her-2 positive colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 420-425.
[14]	Boyang Fan, Ning Wang, Qian Zhang, Guiyu Wang. The progress in research of molecular mechanism of circRNAs regulating colorectal cancer metastasis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 426-430.
[15]	Xin Sun, Haibo Cheng, Weixing Shen. Curative effect mechanism of Xianlian Jiedu decoction in treatment of patients with stage Ⅲ colorectal cancer based on transcriptomics [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 277-283.

Please choose a citation manager

Content to export